|
WO2017017585A1
|
|
Compound, composition and uses thereof
|
|
WO2016203352A2
|
|
Compositions and methods for the treatment of cancer
|
|
WO2016203337A2
|
|
Compositions and methods for the treatment of cancer
|
|
WO2016198971A1
|
|
Compositions and methods for the treatment of hyperglycemia and metabolic syndrome
|
|
WO2016046679A1
|
|
Compositions and methods for the treatment of diabetes and pre-diabetes
|
|
WO2016046680A2
|
|
Compositions and methods for the treatment of liver metabolic diseases
|
|
WO2016132186A1
|
|
Compositions and methods for the treatment of hyperglycemia and metabolic syndrome
|
|
WO2016046675A1
|
|
Compositions and methods for the treatment of neurological diseases
|
|
WO2016046672A1
|
|
Compositions and methods for the treatment of cardiovascular diseases and diabetes
|
|
WO2016046674A1
|
|
Compositions and methods for the treatment of moderate to severe pain
|
|
WO2016046669A2
|
|
Compositions and methods for the treatment of depression and neurological diseases
|
|
WO2016178066A1
|
|
Compositions and methods for the treatment of hyperglycemia and metabolic syndrome
|
|
WO2016181199A1
|
|
Compositions and methods for the treatment of urea cycle disorders and gout
|
|
WO2016046671A1
|
|
Compositions and methods for the treatment of lipid disorders
|
|
WO2016046673A1
|
|
Compositions and methods for the treatment of neurological diseases
|
|
WO2016151372A1
|
|
Compositions and methods for the treatment of hyperglycemia and metabolic syndrome
|
|
WO2016046670A1
|
|
Compositions and methods for the treatment of renal diseases
|
